Forge Therapeutics Enters Into a Pilot Study with Janssen Research & Development, LLC, to Discover Novel Metalloprotein Inhibitors

Jul 21, 2015, 08:00 ET from Forge Therapeutics, Inc.

SAN DIEGO, July 21, 2015 /PRNewswire/ -- Forge Therapeutics, Inc., a biotechnology start-up developing novel small molecule inhibitors that target metalloproteins announced today that it has entered into a Pilot Study with Janssen Research & Development, LLC (JRD) to investigate the Forge Therapeutics chemistry platform in the discovery of novel metalloprotein inhibitors.  The Pilot Study puts to use Forge's expertise and intellectual property in the field of metalloprotein inhibitor discovery.  Forge Therapeutics will receive funding support from JRD. 

"At Forge Therapeutics we are excited to investigate the potential of targeting metalloproteins, which make up over one-third of the proteins in our body, to develop a new and novel class of small molecule inhibitors to treat a wide range of diseases," said Zachary A. Zimmerman, Ph.D., CEO of Forge Therapeutics.  "We kicked-off operations earlier this year in JLABS and within a few months we are entering into a pilot study with JRD to investigate our metalloprotein chemistry, and we believe large pharmaceutical companies can benefit from Forge's approach and platform to bring novel chemistry to validated biological targets."

About Forge Therapeutics, Inc.
Forge Therapeutics, Inc. ("Forge") is a biotechnology start-up that leverages its novel chemistry platform to develop small molecule inhibitors to target metalloproteins.  Metalloproteins are proteins that require metal ions for their biological function and make up over 1/3 of the proteins in the human body.  Forge uses a proprietary approach comprised of molecular modeling for rational drug design along with fundamental knowledge and expertise in bioinorganic chemistry to target metalloproteins.  Forge is uniquely positioned to discover compounds that inhibit metalloproteins through an innovative process developed at the University of California at San Diego.  Forge possesses rights to key intellectual property for metalloprotein inhibitors. The name Forge Therapeutics comes from two definitions for forge: to manipulate (inhibit) a metal object (metalloprotein) and to move forward steadily with a purpose (the Forge team).  Forge Therapeutics, Inc., maintains its headquarters in San Diego, California.  To learn more please visit


SOURCE Forge Therapeutics, Inc.